A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty live
- PDF / 1,149,084 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 141 Views
REVIEW
A bridge for short‑chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non‑alcoholic fatty liver disease positively: by changing gut barrier Wangxin Liu1 · Xianliang Luo1 · Jun Tang1 · Qiufen Mo1 · Hao Zhong1 · Hui Zhang1 · Fengqin Feng1 Received: 26 May 2020 / Accepted: 21 October 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose In previous studies, short-chain fatty acids (SCFAs) have been found to regulate gut microbiota and change gut barrier status, and the potential positive effects of SCFAs on inflammatory bowel disease (IBD), type 1 diabetes mellitus (T1D), and non-alcoholic fatty liver disease (NAFLD) have also been found, but the role of SCFAs in these three diseases is not clear. This review aims to summarize existing evidence on the effects of SCFAs on IBD, T1D, and NHFLD, and correlates them with gut barrier and gut microbiota (gut microbiota barrier). Methods A literature search in PubMed, Web of Science, Springer, and Wiley Online Library up to October 2020 was conducted for all relevant studies published. Results This is a retrospective review of 150 applied research articles or reviews. The destruction of gut barrier may promote the development of IBD, T1D, and NAFLD. SCFAs seem to maintain the gut barrier by promoting the growth of intestinal epithelial cells, strengthening the intestinal tight connection, and regulating the activities of gut microbiota and immune cells, which might result possible beneficial effects on the above three diseases at a certain dose. Conclusions Influencing gut barrier health may be a bridge for SCFAs (especially butyrate) to have positive effects on IBD, T1D, and NAFLD. It is expected that this article can provide new ideas for the subsequent research on the treatment of diseases by SCFAs and help SCFAs be better applied to precise and personalized treatment. Keywords Short-chain fatty acids · Gut barrier · Inflammatory bowel disease · Type 1 diabetes · Non-alcoholic fatty liver disease Abbreviations SCFAs Short-chain fatty acids IBD Inflammatory bowel disease T1D Type 1 diabetes mellitus NAFLD Non-alcoholic fatty liver disease HDAC Inhibiting histone deacetylase GPR G protein-coupled receptors on cells IECs Intestinal epithelial cells * Fengqin Feng [email protected] 1
College of Biosystems Engineering and Food Science, Zhejiang Key Laboratory for Agro‑Food Processing, National Engineering Laboratory of Intelligent Food Technology and Equipment, Key Laboratory for Agro‑Products Postharvest Handling of Ministry of Agriculture and Rural Affairs, Key Laboratory for Agro‑Products Nutritional Evaluation of Ministry of Agriculture, Zhejiang University, No. 866, Yuhangtang Road, Hangzhou 310058, China
TJ Tight junction AJ Adhesion junction Treg Regulatory T cell Th T helper cell IL-x Interleukin-x IFN-γ Interferon-γ TLR2 Toll-like receptor 2 TRAF6 TNF receptor-related factor 6 MCD Methionine choline deficiency ERK Extracellular-regulated protein kinases NASH Non-alcoholic steat
Data Loading...
